Actinium[225Ac]-MNPR-101

N/A

Report date: 2025/10/28 16:07:00

Base Information

Drug NameActinium[225Ac]-MNPR-101
Drug Alias Name225Ac-MNPR-101
ClassificationRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionAnti-Urokinase plasminogen activator surface receptor
TargetsUrokinase plasminogen activator surface receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMonopar Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMonopar Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A